CDC broadens 2026–27 COVID vaccination guidance as fall access emerges
Key Questions
Which strain was selected for the 2026-27 COVID vaccine?
FDA VRBPAC met June 26 and considered XFG ('Stratus') as the leading candidate due to immune escape and dominance, despite WHO recommending LP.8.1. Manufacturer readiness is confirmed under an annualized model.
What real-world effectiveness data exists for recent COVID vaccines?
2025-26 vaccines showed 55% VE in older adults, 59% hospitalization reduction in 65+, and 41% reduction in critical illness. A 30-million-person study found 65-76% lower MACE risk.
Is same-day coadministration of COVID and flu vaccines safe?
Large VA cohort data confirm no increased adverse events with same-day dosing. This supports fall planning despite ACIP limbo.
What guidance has Canada issued for COVID vaccines?
NACI narrowed recommendations to risk-based targeting for high-risk groups. This contrasts with broader US approaches amid ACIP delays.
Why is the LP.8.1 vaccine stuck without recommendations?
It was approved for 65+ and high-risk groups but lacks ACIP endorsement due to lack of quorum. Insurers may not cover it without a recommendation.
Updated Pfizer, Moderna, and Novavax COVID vaccines targeting XFG are approved, and CDC ordering has resumed. A reported October 8 CDC update recommends vaccination for all adults, while emphasizing adults 65+ and high-risk groups, post-infection timing, long-COVID considerations, and product eligibility; states and medical societies continue supporting broad access as insurance, billing, pharmacy authority, and pregnancy pathways vary.